Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$28.35 USD
+0.77 (2.79%)
Updated May 3, 2024 04:00 PM ET
After-Market: $28.34 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cullinan Therapeutics, Inc. [CGEM]
Reports for Purchase
Showing records 1 - 20 ( 43 total )
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Pivotal Zipalertinib Trial Expected to be Fully Enrolled by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Of Many Shapes and Sizes; Initiating on Cullinan Oncology at OUTPERFORM
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cullinan Announces Dosing of First Patient in Phase 1 Trial of CLN-617
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for CGEM 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Looking Forward to Several Data Readouts in 2024 and Complete Enrollment of Pivotal Zipalertinib Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; All Eyes Remain on Zipalertinib Phase 2b Pivotal Study; Phase 3 Study in 1L EGFR Exon20 NSCLC Started
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1 Trial of CLN-978, a Novel T-Cell Engager, in r/r B-NHL
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Compelling Phase 1 Monotherapy CLN-619 Data in Endometrial Cancer Presented at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging CLN-619 Monotherapy Data Planned for Presentation at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; First Clinical Data at EHA for CLN-049 and at ASCO for CLN-619; Lowering PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Six Products Expected to Be in Clinical Development by YE23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E